Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
Five patients with therapy-related acute myeloid leukemia received combination induction chemotherapy with idarubicin, high-dose cytarabine, and etoposide. Complete remission was achieved in all patients with a single course of therapy. Treatment-related toxicity included nausea, vomiting, mucositis, diarrhea, and liver and kidney function abnormalities, and was low in all patients. There were no deaths during induction therapy. We conclude that this combination is well-tolerated in induction of remission in secondary acute myeloid leukemia, and warrants further assessment because of a very good complete remission rate.
Philpott
N
N
Department of Haematology, Royal Marsden Hospital, Sutton, Surrey, UK.
Mehta
J
J
Treleaven
J
J
Powles
R
R
D000208:Acute Disease; D000328:Adult; D000754:Anemia, Refractory, with Excess of Blasts / Q000139:chemically induced / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001803:Blood Transfusion; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000188:drug therapy* / Q000628:therapy; D007953:Leukemia, Radiation-Induced / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects; D012074:Remission Induction; D016879:Salvage Therapy; D016896:Treatment Outcome
D003561:Cytarabine; D005047:Etoposide; D015255:Idarubicin